Pityriasis LichenoidesNCT06889506
Interleukin-4 in Pityriasis Lichenoides Chronica
A study testing skin biopsy and serum sample in people with Pityriasis Lichenoides, run by Cairo University.
Trial summary
assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pityriasis Lichenoides
- What is being tested?
- skin biopsy and serum sample
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2025to Jul 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients with pityriasis lichenoides Chronica (PLC): either with the classical presentation papular or hypo-pigmented macules and patches that proved histopathologically to be PLC.
- Both genders
- Age group ≥ 8 years
Who cannot join
- Patients with other skin diseases
- Patient received treatment for PLC within period less than three months
- Pregnant patients
- Lactating patients
About this study
Official title: Assessment of Interleukin-4 Tissue and Serum Levels in Pityriasis Lichenoides Chronica Patients : a Case- Control Study
assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls.
Read the detailed description
measuring the level of Interleukin 4 in lesional skin and it's serum level using ELIZA in patients with Pityriasis lichenoides chronica and comparing the levels with healthy controls levels
- Conditions
- Pityriasis Lichenoides
- Being tested
- skin biopsy and serum sample
- Medical subject headings
- Pityriasis Lichenoides
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
skin biopsy and serum sampleProcedure or surgery
skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control
| Study group | Role | What they receive |
|---|---|---|
| PLC patients | Active comparator | one skin biopsy (lesional) and serum sample will be taken from every patient Receives: Procedure: skin biopsy and serum sample |
| healthy controls | Experimental | a skin biopsy and serum sample will be taken from each control sample Receives: Procedure: skin biopsy and serum sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of tissue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and normal controls.
measurement of tisssue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and comparing them with normal controls to control and verify the hypothesisof involvement of IL-4 in the pathogenesis of PLC
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2025
- Study start1 Apr 2025 (estimated)
- Primary completionJul 2025 (estimated)
- Study completionJul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pityriasis LichenoidesStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mona Mostafa Korany Mahmoud, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06889506
- Sponsor's protocol ID
- Dermatology 20
- Status last verified
- Jan 2025
- First submitted
- 16 Mar 2025
- Last updated
- 21 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Interleukin-4 Tissue and Serum Levels in Pityriasis Lichenoides Chronica Patients : a Case- Control Study
- ClinicalTrials.gov ID
- NCT06889506
- Acronym / sponsor ID
- Dermatology 20
- Conditions
- Pityriasis Lichenoides
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Apr 2025 (estimated)
- Primary completion
- Jul 2025 (estimated)
- Study completion
- Jul 2025 (estimated)
- First posted
- 21 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls.
Detailed description
measuring the level of Interleukin 4 in lesional skin and it's serum level using ELIZA in patients with Pityriasis lichenoides chronica and comparing the levels with healthy controls levels
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PLC patients | Active comparator | Procedure: skin biopsy and serum sampleone skin biopsy (lesional) and serum sample will be taken from every patient |
| healthy controls | Experimental | Procedure: skin biopsy and serum samplea skin biopsy and serum sample will be taken from each control sample |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with pityriasis lichenoides Chronica (PLC): either with the classical presentation papular or hypo-pigmented macules and patches that proved histopathologically to be PLC.
- Both genders
- Age group ≥ 8 years
Key exclusion criteria (4 listed)
- Patients with other skin diseases
- Patient received treatment for PLC within period less than three months
- Pregnant patients
- Lactating patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| skin biopsy and serum sampleskin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control | Procedure or surgery | PLC patients, healthy controls |
Primary outcome
Assessment of tissue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and normal controls.
Time frame: 6 months
measurement of tisssue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and comparing them with normal controls to control and verify the hypothesisof involvement of IL-4 in the pathogenesis of PLC
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing skin biopsy and serum sample in people with Pityriasis Lichenoides, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of tissue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and normal controls. (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2025.